BMO Capital Starts Nightstar Therapeutics (NITE) at Outperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/18/2026
- Tech selloff weighs down Wall Street as bond yields climb
- Baidu slips as Q2 results miss estimates despite growth in AI cloud business
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Home Depot beats estimates, reaffirms fiscal 2026 guidance
- Citi says positioning risk is shifting from short squeezes to profit-taking
- Wall Street indexes slip as oil prices rise, retail results awaited
- Tech selloff weighs down Wall Street as bond yields climb
- Micron rises as White House presses Apple to avoid Chinese memory chips
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- Francisco Partners to acquire Weave Communications for $650M
Wedbush Starts Nightstar Therapeutics (NITE) at Outperform
October 23, 2017 6:17 AM EDTWedbush initiates coverage on Nightstar Therapeutics (NASDAQ: NITE) with a Outperform rating and a price target of $29.00.
Analyst David Nierengarten views shares as undervalued, given NITEs lead asset, NSR-REP1, is set to enter Ph 3 with curative potential for choroideremia (CHM), a rare... More
UPDATE: Leerink Partners Starts Nightstar Therapeutics (NITE) at Outperform
October 23, 2017 6:13 AM EDT(Updated - October 23, 2017 7:45 AM EDT)
(updated to expand analyst comment)
Leerink Partners initiates coverage on Nightstar Therapeutics (NASDAQ: NITE) with a Outperform rating and a price target of $25.00.
Analyst Joseph Schwartz called it a 'White Night' for Retinal Dystrophies. The... More
Jefferies Starts Nightstar Therapeutics (NITE) at Buy
October 23, 2017 3:13 AM EDTJefferies initiates coverage on Nightstar Therapeutics (NASDAQ: NITE) with a Buy rating and a price target of $25.00.
Analyst Michael Yee likes the pure-play profile and the company's differentiation through a sole focus on retinal diseases. The analyst believes the company pivotal Phase 3... More
